These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18501853)

  • 1. Hepatitis C vaccine: supply and demand.
    Strickland GT; El-Kamary SS; Klenerman P; Nicosia A
    Lancet Infect Dis; 2008 Jun; 8(6):379-86. PubMed ID: 18501853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2011 Dec; 21(12):1811-30. PubMed ID: 22022980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.
    Alvarez-Lajonchere L; Dueñas-Carrera S
    Int Rev Immunol; 2012 Jun; 31(3):223-42. PubMed ID: 22587022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.
    Houghton M
    Immunol Rev; 2011 Jan; 239(1):99-108. PubMed ID: 21198667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods to Evaluate Novel Hepatitis C Virus Vaccines.
    Ahlén G; Frelin L
    Methods Mol Biol; 2016; 1403():221-44. PubMed ID: 27076133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
    Torresi J; Johnson D; Wedemeyer H
    J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for hepatitis C vaccine.
    Bhopale GM; Nanda RK
    Acta Virol; 2004; 48(4):215-21. PubMed ID: 15745044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of hepatitis C virus protein epitopes for vaccine development.
    Koshy R; Inchauspé G
    Trends Biotechnol; 1996 Oct; 14(10):364-9. PubMed ID: 8987634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design.
    Smyk-Pearson S; Tester IA; Lezotte D; Sasaki AW; Lewinsohn DM; Rosen HR
    J Infect Dis; 2006 Aug; 194(4):454-63. PubMed ID: 16845628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine development for hepatitis C.
    Lechmann M; Liang TJ
    Semin Liver Dis; 2000; 20(2):211-26. PubMed ID: 10946425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2012 Apr; 22(4):391-415. PubMed ID: 22455502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
    Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
    Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges for HCV vaccine development in HIV-HCV coinfection.
    Lambotin M; Barth H; Moog C; Habersetzer F; Baumert TF; Stoll-Keller F; Fafi-Kremer S
    Expert Rev Vaccines; 2012 Jul; 11(7):791-804. PubMed ID: 22913257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.
    Yusim K; Fischer W; Yoon H; Thurmond J; Fenimore PW; Lauer G; Korber B; Kuiken C
    J Gen Virol; 2010 May; 91(Pt 5):1194-206. PubMed ID: 20053820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for a vaccine against the hepatitis C virus.
    Houghton M; Abrignani S
    Nature; 2005 Aug; 436(7053):961-6. PubMed ID: 16107836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Success and failure of virus-specific T cell responses in hepatitis C virus infection.
    Neumann-Haefelin C; Thimme R
    Dig Dis; 2011; 29(4):416-22. PubMed ID: 21894013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.
    Feinstone SM; Hu DJ; Major ME
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S25-32. PubMed ID: 22715210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice.
    Huret C; Desjardins D; Miyalou M; Levacher B; Amadoudji Zin M; Bonduelle O; Combadière B; Dalba C; Klatzmann D; Bellier B
    Vaccine; 2013 Mar; 31(11):1540-7. PubMed ID: 22634300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like particle-based vaccines against hepatitis C virus infection.
    Bellier B; Klatzmann D
    Expert Rev Vaccines; 2013 Feb; 12(2):143-54. PubMed ID: 23414406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.